Top Markets
Coin of the day
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
주식 순위 #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
주가
$0.1
마지막 동기화: 2024-06-18
시가총액
$1.31M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Pascal Biosciences Inc. (PSCBF)

카테고리

Pascal Biosciences Inc. (PSCBF)의 매출
Feb 2024 기준 매출 TTM: $700.83K
Pascal Biosciences Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $700.83K입니다. 2022년에 회사는 0.00의 수익을 올렸으며 이는 2021년의 0.00 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Pascal Biosciences Inc.의 수익 기록 (2019 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $700.83K 41.81%
2023 $494.20K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B 1,801,231.33%
US
$6.02B 859,063.16%
NL
- -
CH
- -
KR
$10.11B 1,442,584.10%
BE